Whole Genome Sequencing Market Size, Share, Trends & Forecast 2030 | Exclusive report by DataM Intelligence

Leander, Texas and Tokyo, Japan - Feb.04.2026
As per DataM intelligence research report "Global Whole Genome Sequencing market is growing at a CAGR of 15% during the forecast period 2024-2031."

The market is driven by advancements in genomics and precision medicine. Clinical diagnostics, oncology, and research applications dominate adoption. Hospitals, research institutes, and biotech companies are key end-users. Declining sequencing costs and personalized medicine initiatives fuel growth.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/whole-genome-sequencing-market?prasad
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Whole Genome Sequencing Market: Competitive Intelligence
Illumina; Inc., Thermo Fisher Scientific, Inc., Oxford Nanopore Technologies, QIAGEN, Agilent Technologies, PerkinElmer Genomics

The Whole Genome Sequencing Market is being strongly advanced by Illumina, Inc., Thermo Fisher Scientific, Inc., Oxford Nanopore Technologies, QIAGEN, Agilent Technologies, and PerkinElmer Genomics, as these companies collectively expand access to high-throughput, accurate, and scalable genomic analysis. Their sequencing platforms, reagents, and bioinformatics tools support applications across clinical diagnostics, precision medicine, population genomics, and biomedical research. By improving sequencing speed, data quality, and cost efficiency, these companies contribute to the growth, reliability, and clinical integration of the Whole Genome Sequencing Market. This collective progress enables broader adoption of genomics in healthcare, research, and public health initiatives.

The complementary strengths of these players create strong momentum within the Whole Genome Sequencing Market by aligning sequencing technologies, sample preparation, and data interpretation capabilities. Illumina, Inc. and Thermo Fisher Scientific, Inc. provide high-throughput sequencing systems and consumables that support large-scale research and clinical workflows. Oxford Nanopore Technologies adds flexibility with long-read and real-time sequencing solutions, while QIAGEN and Agilent Technologies strengthen upstream sample preparation, target enrichment, and workflow optimization. PerkinElmer Genomics complements this ecosystem with integrated genomic services and analytics. Together, these capabilities accelerate innovation, enhance workflow efficiency, and strengthen competitive positioning across the market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/whole-genome-sequencing-market?prasad
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Fund Raisings

✅ January 2026 - Illumina Inc. (North America)
Illumina invested $80 million to expand next-generation sequencing platform development. The funding supports clinical and research-scale genome sequencing.

✅ December 2025 - Oxford Nanopore Technologies (Europe)
Oxford Nanopore raised $65 million to enhance long-read sequencing technology. The capital accelerates product innovation and global adoption.

✅ November 2025 - Pacific Biosciences (North America)
Pacific Biosciences secured $55 million to advance high-accuracy genome sequencing systems. The funding strengthens clinical diagnostics applications.

Product Launches & Partnerships

✅ January 2026 - Illumina Inc. (North America)
Illumina launched an upgraded whole genome sequencing platform with faster throughput. Partnerships with clinical labs support large-scale genomic studies.

✅ December 2025 - Oxford Nanopore Technologies (Europe)
Oxford Nanopore introduced portable genome sequencers for decentralized testing. The launch supports research and infectious disease surveillance.

✅ October 2025 - Pacific Biosciences (North America)
Pacific Biosciences partnered with academic institutions for precision genomics research. The collaboration accelerates clinical validation.

Mergers & Acquisitions

✅ January 2026 - Illumina Inc. (North America)
Illumina acquired a bioinformatics analytics firm. The acquisition enhances genome data interpretation capabilities.

✅ November 2025 - Oxford Nanopore Technologies (Europe)
Oxford Nanopore acquired a sequencing chemistry startup. The move strengthens technology differentiation.

✅ October 2025 - Pacific Biosciences (North America)
Pacific Biosciences acquired a sample preparation company. The deal improves workflow efficiency.

Segment Covered in the Whole Genome Sequencing Market:
By Product
The market is segmented into consumables 45%, instruments 30%, and services 25%, with consumables dominating due to recurring demand for sequencing reagents, kits, and sample preparation products. Instruments hold a significant share driven by ongoing investments in next-generation sequencing platforms, while services are growing rapidly with increasing outsourcing of sequencing and data analysis. Rising sequencing volumes and declining per-genome costs drive product adoption.

By Application
Applications include diagnostics 30%, drug discovery 25%, precision medicine 20%, epidemiological studies 15%, and others 10%, with diagnostics dominating due to increasing use of whole genome sequencing in rare disease diagnosis, oncology, and inherited disorders. Drug discovery and precision medicine are high-growth segments driven by genomics-driven target identification and personalized therapies. Expansion of genomic research supports application growth.

By Type
Based on type, the market is divided into large whole genome sequencing 60% and small whole genome sequencing 40%, with large WGS dominating due to its extensive use in population-scale genomics projects, national genome initiatives, and advanced research studies. Small WGS is gaining traction in clinical diagnostics and targeted sequencing workflows. Technological advancements and reduced sequencing costs drive type-based adoption.

By End User
End users include academic & research institutes 35%, hospitals and diagnostic centers 30%, pharmaceutical & biotechnology companies 25%, and others 10%, with academic and research institutes dominating due to large-scale genomics projects and government-funded research programs. Hospitals and diagnostics centers are growing rapidly with increasing clinical adoption, while pharma and biotech companies leverage WGS for drug discovery and development. Rising genomics integration in healthcare drives end-user growth.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=whole-genome-sequencing-market
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Analysis
North America - 40% Share
North America leads with 40% share driven by strong presence of genomics research institutions, sequencing technology providers, and government genome initiatives in the U.S. and Canada. Consumables dominate product demand. Diagnostics and drug discovery lead applications. Academic institutes and hospitals are major end-users. Advanced healthcare infrastructure and high R&D spending drive market growth.

Europe - 25% Share
Europe holds 25% share with strong adoption in the U.K., Germany, and France. Consumables and services dominate. Diagnostics and epidemiological studies are key applications. Academic institutions and hospitals lead end-user adoption. Government-supported genome programs and research collaborations support market expansion.

Asia Pacific - 20% Share
Asia Pacific accounts for 20% share driven by China, Japan, and South Korea. Instruments and consumables dominate. Precision medicine and diagnostics are fast-growing applications. Academic institutes and pharmaceutical companies are major end-users. Expanding genomics infrastructure and government investments drive market growth.

Latin America - 5% Share
Latin America records 5% share led by Brazil and Mexico. Consumables dominate. Diagnostics and epidemiological studies lead applications. Academic institutes and diagnostic centers are primary end-users. Improving research capabilities support gradual market adoption.

Middle East & Africa - 10% Share
Middle East & Africa hold 10% share due to increasing investments in genomic research in UAE, Saudi Arabia, and South Africa. Services and consumables dominate. Diagnostics and precision medicine are emerging applications. Hospitals and research institutes lead end-user adoption. Growing healthcare modernization supports market growth.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.